C-Rad (CRAD-B.ST) Stock Analysis & AI Equity Report
C-Rad (CRAD-B.ST) overview
C-Rad (CRAD-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, C-Rad reported revenue of SEK 469m and operating profit of SEK 70.2m; the year-end share price was 30.00 SEK and market capitalisation was SEK 1,015m. C-Rad is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get C-Rad's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About C-Rad
C-RAD AB develops surface-guided radiation therapy solutions for cancer treatment. Its systems use high-speed 3D cameras and related software to support patient positioning and monitor motion during radiotherapy, helping clinics deliver treatment more accurately while protecting healthy tissue. The company sells its products and services to hospitals and cancer centers internationally.
Generate the C-Rad report
C-Rad is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for C-Rad and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.